The DNA of Things with Dr. Jeremy Koenig

Episode 57: Biohacking the Future: Mac Davis on Self-Experimentation and Plasmid Gene Therapy

Dr. Jeremy Koenig Episode 57

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 57:15

In this episode, Dr. Jeremy Koenig talks with Mac Davis, biotech entrepreneur and founder of Minicircle, Inc. They explore Mac's unconventional journey from cryptocurrency to pioneering plasmid-based gene therapies, diving into revolutionary approaches to genetic enhancement and philosophical perspectives on human evolution.


Key Takeaways:

  • Minicircle's Innovation: Mac Davis has developed a gene therapy platform using circular DNA (plasmids) that can deliver targeted genes to enhance human health and potentially extend lifespan.
  • Self-Experimentation Journey: Mac and his co-founder tested their first follistatin gene therapy on themselves after animal studies, experiencing significant muscle growth, fat reduction, and improved wellbeing.
  • Adapting to Modern Challenges: Minicircle therapies could help humans adapt to rapidly changing environmental conditions and toxins (microplastics, PFAS) that our bodies didn't evolve to handle.
  • Beyond Disease Treatment: The therapies target both disease conditions (HIV, ALS, Crohn's) and potential enhancement of human capabilities through genes like klotho, associated with higher IQ and improved brain health.
  • Biology as Information: Mac describes plasmids as an "information technology" - similar to books or websites - that can spread beneficial biological information between people.
  • The Future of Enhancement: "Plasmids work" is Mac's central message - they represent an accessible, effective technology for gene transfer with vast untapped potential for intentional human biological enhancement.

 LINKS:

https://www.drjeremykoenig.com/
https://www.instagram.com/drjeremykoenig/
https://www.youtube.com/@drjeremykoenig


Here's the link for this week's episode: https://drjeremykoenig.substack.com/.